Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MDM4 | O15151 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26160451 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29446045 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29356265 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29401309 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29564442 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL119043 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29349978 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29508222 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL29446029 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 | |
| SCHEMBL119044 | 1.00 | CASP3 (0.57) | CASP3KMT2AMDM4TP53EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 428 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | JIANGXI NORMAL UNIVERSITY (CN) | 2023-08-03 | — | — | US | claimed |
| EP-1212348-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | Consensus Pharmaceuticals, Inc. (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020019061-A1 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | IWA, LLC | 2002-02-14 | — | — | US | claimed |
| WO-2001016160-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | CONSENSUS PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| EP-4748847-A1 | PEPTIDE COMPLEX HAVING VEGFR -2 AGONIST ACTIVITY | Peptidream Inc (JP) | 2026-05-27 | — | — | EP | disclosed |
| CN-122075733-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4602064-B1 | METHOD OF MANUFACTURING A PEPTIDE WITH A LYSINE DERIVATIVE | BACHEM HOLDING AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| EP-4659764-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2025-12-10 | — | — | EP | disclosed |
| EP-4631955-A1 | PURIFICATION METHOD AND PRODUCTION METHOD OF CYCLIC PEPTIDE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-15 | — | — | EP | disclosed |
| US-20250288587-A1 | Methods of Treating Fibrosis | ATHIRA PHARMA, INC. (US) | 2025-09-18 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-6479508-B1 | INHIBITOR OF RNA DEPENDENT RNA POLYMERASE ACTIVITY OF THE ENZYME NS5B ENCODED BY HEPATITIS C VIRUS FOR TREATMENT AND PREVENTION OF HEPATITIS C INFECTIONS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-11-12 | — | — | US | disclosed |
| US-6448281-B1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION; TREATMENT OF HEPATITIS C | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-09-10 | — | — | US | disclosed |
| EP-1212348-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | Consensus Pharmaceuticals, Inc. (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020019061-A1 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | IWA, LLC | 2002-02-14 | — | — | US | disclosed |
| WO-2001016160-A2 | PURIFICATION AND ANALYSIS OF CYCLIC PEPTIDE LIBRARIES, AND COMPOSITIONS THEREOF | CONSENSUS PHARMACEUTICALS, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| EP-0546055-B1 | POLYETHYLENE GLYCOL DERIVATIVES FOR SOLID-PHASE APPLICATIONS | UNIV MINNESOTA (US) | 1996-07-10 | — | — | EP | disclosed |
| US-4914151-A | Resin-linker combination for the solid-phase synthesis of peptides and intermediates | BACHEM FEINCHEMIKALEIN A.G. (CH) | 1990-04-03 | — | — | US | disclosed |
| US-4831084-A | Resin-linker combination for the solid-phase synthesis of peptides and intermediates | BACHEM FEINCHEMIKALIEN A.G. (CH) | 1989-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242572-A1 | a-CARBONYL ALKENYL ESTER PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ACSL1, ACSL4, WEE1 | CASP3 3706/4885KMT2A 3061/4885MDM4 3883/4885 |
| US-20250288587-A1 | Methods of Treating Fibrosis | HDGF, HGF, MMP1 | CASP3 675/4885KMT2A 3891/4885MDM4 4049/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CASP3 343/4885KMT2A 4608/4885MDM4 3559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.